Elanco Animal Health (NYSE:ELAN) Updates Q3 2026 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) issued an update on its third quarter 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 0.190-0.220 for the period, compared to the consensus EPS estimate of 0.190. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Elanco Animal Health also updated its FY 2026 guidance to 1.100-1.160 EPS.

Elanco Animal Health Stock Down 8.9%

Shares of ELAN traded down $2.33 during mid-day trading on Thursday, hitting $23.89. 11,295,325 shares of the company traded hands, compared to its average volume of 5,440,066. The company has a market capitalization of $11.93 billion, a PE ratio of -47.62, a price-to-earnings-growth ratio of 1.67 and a beta of 1.67. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60. The business has a 50 day moving average of $24.73 and a 200 day moving average of $24.10. Elanco Animal Health has a 1-year low of $15.50 and a 1-year high of $27.98.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.07. The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. Elanco Animal Health’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.26 EPS. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Equities research analysts anticipate that Elanco Animal Health will post 1.11 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ELAN. Citigroup increased their price target on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Morgan Stanley upped their price objective on shares of Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a report on Wednesday, July 22nd. Wall Street Zen lowered shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. Piper Sandler restated an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, June 29th. Finally, KeyCorp upped their price target on shares of Elanco Animal Health from $29.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Elanco Animal Health presently has an average rating of “Moderate Buy” and a consensus price target of $28.82.

Insider Activity at Elanco Animal Health

In related news, CEO Jeffrey N. Simmons purchased 4,971 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were purchased at an average price of $20.09 per share, with a total value of $99,867.39. Following the purchase, the chief executive officer owned 171,971 shares of the company’s stock, valued at $3,454,897.39. The trade was a 2.98% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Rajeev A. Modi purchased 4,911 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The stock was bought at an average cost of $20.35 per share, with a total value of $99,938.85. Following the acquisition, the insider owned 160,812 shares in the company, valued at $3,272,524.20. This represents a 3.15% increase in their position. The SEC filing for this purchase provides additional information. 1.14% of the stock is currently owned by company insiders.

Key Stories Impacting Elanco Animal Health

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Elanco reported second-quarter adjusted EPS of $0.34, above the $0.27 consensus estimate, while revenue rose 10.2% year over year to $1.368 billion, exceeding expectations of $1.31 billion. Elanco Animal Health Reports Second Quarter 2026 Results
• Positive Sentiment: Management raised full-year 2026 adjusted EPS guidance to $1.10-$1.16 from its prior outlook, increased revenue guidance to $5.09-$5.14 billion, lifted adjusted EBITDA guidance to $1.01-$1.035 billion, and raised its innovation-revenue target to $1.25 billion. Zenrelia reportedly reached blockbuster status. Elanco posts Q2 beat as Zenrelia hits blockbuster status
• Positive Sentiment: KeyCorp raised its price target for ELAN to $30 from $29 and maintained an “overweight” rating, indicating continued analyst confidence in the company’s growth outlook. KeyCorp price target update
• Neutral Sentiment: Third-quarter guidance calls for adjusted EPS of $0.19-$0.22 and revenue of approximately $1.2 billion, broadly in line with consensus. That limited near-term upside may be contributing to the weaker stock reaction.
• Negative Sentiment: Although adjusted results were strong, reported net income was $54 million and reported EPS was $0.11. Elanco also remains leveraged at 3.1 times adjusted EBITDA, so investors may remain cautious about debt reduction and the company’s negative GAAP net margin.
• Neutral Sentiment: A Zacks comparison with Addus HomeCare focuses on relative valuation rather than a new company-specific catalyst, potentially prompting investors to reassess whether ELAN’s recent gains adequately reflect its improved outlook. ADUS vs. ELAN: Which Stock Is the Better Value Option?

Institutional Trading of Elanco Animal Health

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP boosted its holdings in Elanco Animal Health by 1.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 25,082,545 shares of the company’s stock worth $567,622,000 after buying an additional 373,869 shares during the last quarter. UBS Group AG raised its holdings in shares of Elanco Animal Health by 56.7% during the third quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock valued at $331,669,000 after acquiring an additional 5,961,457 shares during the last quarter. Fuller & Thaler Asset Management Inc. lifted its position in shares of Elanco Animal Health by 16.1% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 5,771,622 shares of the company’s stock valued at $130,612,000 after acquiring an additional 799,745 shares in the last quarter. Invesco Ltd. lifted its position in shares of Elanco Animal Health by 336.0% in the fourth quarter. Invesco Ltd. now owns 4,789,037 shares of the company’s stock valued at $108,376,000 after acquiring an additional 3,690,735 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Elanco Animal Health by 104.5% in the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after acquiring an additional 2,445,872 shares during the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.